The efficacy and safety of different bismuth agents in Helicobacter pylori first-line eradication: A multicenter, randomized, controlled clinical trial

Yaping Cao, Jian Zhang, Yuan Liu, Lifeng Zhang, Lu Wang, Jie Wang, Ying Qi, Huanhuan Lv, Juan Liu, Lijuan Huo, Xiaoguo Wei, Yongquan Shi, Yaping Cao, Jian Zhang, Yuan Liu, Lifeng Zhang, Lu Wang, Jie Wang, Ying Qi, Huanhuan Lv, Juan Liu, Lijuan Huo, Xiaoguo Wei, Yongquan Shi

Abstract

Background: The aim of this study was to evaluate the efficacy and safety of bismuth pectin capsules and bismuth pectin granules in the first-line quadruple treatment of Helicobacter pylori (H. pylori).

Methods: This study was a multicenter, randomized, open-labelled controlled clinical trial. Patients with a H. pylori infection were randomized into 4 groups (1:1:1:1) and treated with a 14-day bismuth-containing quadruple therapy. The 4 groups received either bismuth potassium citrate capsules (220 mg), colloidal bismuth pectin capsules (200 mg), bismuth pectin granules (150 mg), or bismuth pectin granules (300 mg). The primary outcome was the eradication rate of H. pylori. The secondary outcomes included symptom improvement, patient compliance, and incidence of adverse events. This study was registered at ClinicalTrials.gov (NCT04209933).

Results: A total of 240 patients were included in this study, and 211 patients completed the follow-up. An intention-to-treat analysis showed that the H. pylori eradication rates of the 4 groups were 73.3%, 76.7%, 75.0%, and 71.7%, respectively. The per-protocol analysis showed that the H. pylori eradication rates of the 4 groups were 86.3%, 82.1%, 83.3%, and 86.0%. There was no significant difference among the 4 groups in the H. pylori eradication rate (P > .05). There were also no significant differences in the symptom improvement rate, overall adverse reaction rate, or patient compliance among the 4 groups.

Conclusions: Bismuth pectin capsules and bismuth pectin granules had similar efficacy and safety for H. pylori eradication compared to bismuth potassium citrate. These data suggest that bismuth pectin can be an alternative to bismuth potassium citrate to eradicate H. pylori when using bismuth-containing quadruple therapy.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

Figures

Figure 1
Figure 1
Flow diagram of the study.

References

    1. Cover TL, Blaser MJ. Helicobacter pylori in health and disease. Gastroenterology 2009;136:1863–73.
    1. Peleteiro B, Bastos A, Ferro A, Lunet N. Prevalence of Helicobacter pylori infection worldwide: a systematic review of studies with national coverage. Dig Dis Sci 2014;59:1698–709.
    1. Malfertheiner P, Megraud F, O’morain CA, et al. . Management of Helicobacter pylori infection-the Maastricht V/Florence Consensus Report. Gut 2017;66:06–30.
    1. De Brito BB, Da Silva FAF, Soares AS, et al. . Pathogenesis and clinical management of Helicobacter pylori gastric infection. World J Gastroenterol 2019;25:5578–89.
    1. Ford AC, Delaney BC, Forman D, Moayyedi P. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004;99:1833–55.
    1. Lee YC, Chiang TH, Chou CK, et al. . Association between Helicobacter pylori eradication and gastric cancer incidence: a systematic review and meta-analysis. Gastroenterology 2016;150:1113–24.e5.
    1. Choi IJ, Kook MC, Kim YI, et al. . Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085–95.
    1. Fang JY, Du YQ, Liu WZ, et al. . Chinese consensus on chronic gastritis (2017, Shanghai). J Dig Dis 2018;19:182–203.
    1. Mathew J. H pylori eradication therapy reduces gastric cancer in patients with or without gastric neoplasia. Ann Intern Med 2020;173:JC32.
    1. Sugano K, Tack J, Kuipers EJ, et al. . Kyoto global consensus report on Helicobacter pylori gastritis. Gut 2015;64:1353–67.
    1. O’Morain NR, Dore MP, O’Connor AJP, Gisbert JP, O’Morain CA. Treatment of Helicobacter pylori infection in 2018. Helicobacter 2018;23: (Suppl 1): e12519.
    1. O’Connor A, Lamarque D, Gisbert JP, O’Morain C. Treatment of Helicobacter pylori infection 2017. Helicobacter 2017;22: (Suppl 1): e12410.
    1. Gao W, Cheng H, Hu F, et al. . The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010;15:460–6.
    1. Camargo MC, Garcia A, Riquelme A, et al. . The problem of Helicobacter pylori resistance to antibiotics: a systematic review in Latin America. Am J Gastroenterol 2014;109:485–95.
    1. Rasheed F, Campbell BJ, Alfizah H, et al. . Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance. Helicobacter 2014;19:387–99.
    1. Fischbach W, Malfertheiner P. Helicobacter pylori infection. Dtsch Arztebl Int 2018;115:429–36.
    1. Savoldi A, Carrara E, Graham DY, Conti M, Tacconelli E. Prevalence of antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis in World Health Organization regions. Gastroenterology 2018;155:1372–82.e17.
    1. Liu WZ, Xie Y, Lu H, et al. . Fifth Chinese National Consensus Report on the management of Helicobacter pylori infection. Helicobacter 2018;23:e12475.
    1. Dore MP, Lu H, Graham DY. Role of bismuth in improving Helicobacter pylori eradication with triple therapy. Gut 2016;65:870–8.
    1. Graham DY, Dore MP, Lu H. Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies. Expert Rev Anti Infect Ther 2018;16:679–87.
    1. Yu L, Luo L, Long X, et al. . High-dose PPI-amoxicillin dual therapy with or without bismuth for first-line Helicobacter pylori therapy: a randomized trial. Helicobacter 2019;24:e12596.
    1. Alkim H, Koksal A, Boga S, Sen I, Alkim C. Role of bismuth in the eradication of Helicobacter pylori. Am J Ther 2017;24:e751–7.
    1. Lambert JR, Midolo P. The actions of bismuth in the treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11: (Suppl 1): 27–33.
    1. Ko SW, Kim YJ, Chung WC, Lee SJ. Bismuth supplements as the first-line regimen for Helicobacter pylori eradication therapy: systemic review and meta-analysis. Helicobacter 2019;24:e12565.
    1. Kim SE, Roh JH, Park MI, et al. . Effect of 7-day bismuth quadruple therapy versus 14-day moxifloxacin triple therapy for second-line Helicobacter pylori eradication therapy. Korean J Gastroenterol 2019;73:26–34.
    1. Zagari RM, Romiti A, Ierardi E, et al. . The “three-in-one” formulation of bismuth quadruple therapy forHelicobacter pylorieradication with or without probiotics supplementation: efficacy and safety in daily clinical practice. Helicobacter 2018;23:e12502.
    1. Fiorini G, Zullo A, Saracino IM, Gatta L, Pavoni M, Vaira D. Pylera and sequential therapy for first-line Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2018;30:621–5.
    1. Chen L, He J, Wang L, et al. . Efficacies of different proton pump inhibitor-based 14-day bismuth–furazolidone quadruple regimens for the initial eradication of Helicobacter pylori in the southeast coastal region of China: an open-label, randomized clinical trial. Clin Exp Med 2018;18:569–76.
    1. Wang JL, Liu XY, Nie Y, et al. . Thinking about the advantages and disadvantages of bismuth agent in clinical application. Chin J Internal Med 2012;51:932–4.
    1. Ge R, Chen Z, Zhou Q. The actions of bismuth in the treatment of Helicobacter pylori infections: an update. Metallomics 2012;4:239.
    1. Yang XJ, Chen SB. Adverse reactions of colloidal acid. New Drugs Clin Remedies 1992;03:178–80.
    1. Qi CF. Clinical efficacy and pharmaceutical toxicology of colloid pectin bismuth capsule. Heilongjiang Traditi Chin Med 2008;11:47.
    1. Mcnicholl AG, Bordin DS, Lucendo A, et al. . Combination of bismuth and standard triple therapy eradicates Helicobacter pylori infection in more than 90% of patients. Clin Gastroenterol Hepatol 2020;18:89–98.
    1. Lu XD. Effect of colloidal bismuth pectin 200 mg bid 10-day quadruple therapy on helicobacter pylori eradication. World Latest Med Inf 2019;19:212–8.
    1. Zhang QY, Li Y. Efficacy of three bismuth-containing quadruple therapy for eradication of Helicobacter pylori. Chin J Gastroenterol Hepatol 2019;28:886–9.
    1. Fu LH. Comparison of efficacy of triple therapy with bismuth-containing quadruple therapy and sequential therapy in the treatment of Helicobacter pylori infection. Chin J Clin Rational Drug Use 2020;13:57–8.
    1. Ford AC, Malfertheiner P, Giguere M, Santana J, Khan M, Moayyedi P. Adverse events with bismuth salts for Helicobacter pylori eradication: systematic review and meta-analysis. World J Gastroenterol 2008;14:7361–70.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa